...
rgnx-img

Regenxbio Inc, Common Stock

RGNX

NSQ

$8.411

-$0.06

(-0.71%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$419.65M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
413.25K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.23
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$8.06 L
$28.8 H
$8.411

About Regenxbio Inc, Common Stock

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRGNXSectorS&P500
1-Week Return-13.22%-3.39%0.2%
1-Month Return-16.55%-1.92%2.72%
3-Month Return-34.59%-10.54%7.31%
6-Month Return-27.23%-4.47%10.44%
1-Year Return-56.59%4.06%27.53%
3-Year Return-73.97%0.94%30.88%
5-Year Return-80.3%36.67%89.21%
10-Year Return-72.18%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue35.23M154.57M470.35M112.72M90.24M[{"date":"2019-12-31","value":7.49,"profit":true},{"date":"2020-12-31","value":32.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":23.97,"profit":true},{"date":"2023-12-31","value":19.19,"profit":true}]
Cost of Revenue8.24M35.71M51.83M54.55M37.21M[{"date":"2019-12-31","value":15.11,"profit":true},{"date":"2020-12-31","value":65.48,"profit":true},{"date":"2021-12-31","value":95.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":68.22,"profit":true}]
Gross Profit26.99M118.85M418.51M58.18M53.03M[{"date":"2019-12-31","value":6.45,"profit":true},{"date":"2020-12-31","value":28.4,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":13.9,"profit":true},{"date":"2023-12-31","value":12.67,"profit":true}]
Gross Margin76.61%76.89%88.98%51.61%58.76%[{"date":"2019-12-31","value":86.1,"profit":true},{"date":"2020-12-31","value":86.42,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":58,"profit":true},{"date":"2023-12-31","value":66.04,"profit":true}]
Operating Expenses175.99M238.09M258.53M321.06M321.16M[{"date":"2019-12-31","value":54.8,"profit":true},{"date":"2020-12-31","value":74.13,"profit":true},{"date":"2021-12-31","value":80.5,"profit":true},{"date":"2022-12-31","value":99.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(149.00M)(119.23M)159.98M(262.88M)(268.13M)[{"date":"2019-12-31","value":-93.14,"profit":false},{"date":"2020-12-31","value":-74.53,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-164.32,"profit":false},{"date":"2023-12-31","value":-167.6,"profit":false}]
Total Non-Operating Income/Expense54.46M16.72M(44.29M)(40.44M)(5.08M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":30.71,"profit":true},{"date":"2021-12-31","value":-81.33,"profit":false},{"date":"2022-12-31","value":-74.26,"profit":false},{"date":"2023-12-31","value":-9.34,"profit":false}]
Pre-Tax Income(97.49M)(106.01M)141.25M(280.40M)(263.65M)[{"date":"2019-12-31","value":-69.02,"profit":false},{"date":"2020-12-31","value":-75.05,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-198.52,"profit":false},{"date":"2023-12-31","value":-186.66,"profit":false}]
Income Taxes(2.75M)5.24M13.41M(84.00K)(152.00K)[{"date":"2019-12-31","value":-20.55,"profit":false},{"date":"2020-12-31","value":39.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.63,"profit":false},{"date":"2023-12-31","value":-1.13,"profit":false}]
Income After Taxes(94.73M)(111.25M)127.84M(280.32M)(263.49M)[{"date":"2019-12-31","value":-74.1,"profit":false},{"date":"2020-12-31","value":-87.02,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-219.27,"profit":false},{"date":"2023-12-31","value":-206.11,"profit":false}]
Income From Continuous Operations(94.73M)(111.25M)127.84M(280.32M)(260.54M)[{"date":"2019-12-31","value":-74.1,"profit":false},{"date":"2020-12-31","value":-87.02,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-219.27,"profit":false},{"date":"2023-12-31","value":-203.8,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(94.73M)(111.25M)127.84M(280.32M)(263.49M)[{"date":"2019-12-31","value":-74.1,"profit":false},{"date":"2020-12-31","value":-87.02,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-219.27,"profit":false},{"date":"2023-12-31","value":-206.11,"profit":false}]
EPS (Diluted)(2.59)(2.80)2.74(6.50)(6.03)[{"date":"2019-12-31","value":-94.53,"profit":false},{"date":"2020-12-31","value":-102.19,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-237.23,"profit":false},{"date":"2023-12-31","value":-220.07,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RGNX
Cash Ratio 2.49
Current Ratio 3.05
Quick Ratio 3.17

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RGNX
ROA (LTM) -26.03%
ROE (LTM) -71.87%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RGNX
Debt Ratio Lower is generally better. Negative is bad. 0.42
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.58

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RGNX
Trailing PE NM
Forward PE NM
P/S (TTM) 4.98
P/B 1.39
Price/FCF NM
EV/R 2.94
EV/Ebitda NM
PEG 0.26

FAQs

What is Regenxbio Inc share price today?

Regenxbio Inc (RGNX) share price today is $8.411

Can Indians buy Regenxbio Inc shares?

Yes, Indians can buy shares of Regenxbio Inc (RGNX) on Vested. To buy Regenxbio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RGNX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Regenxbio Inc be purchased?

Yes, you can purchase fractional shares of Regenxbio Inc (RGNX) via the Vested app. You can start investing in Regenxbio Inc (RGNX) with a minimum investment of $1.

How to invest in Regenxbio Inc shares from India?

You can invest in shares of Regenxbio Inc (RGNX) via Vested in three simple steps:

  • Click on Sign Up or Invest in RGNX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Regenxbio Inc shares
What is Regenxbio Inc 52-week high and low stock price?

The 52-week high price of Regenxbio Inc (RGNX) is $28.8. The 52-week low price of Regenxbio Inc (RGNX) is $8.06.

What is Regenxbio Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Regenxbio Inc (RGNX) is

What is Regenxbio Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Regenxbio Inc (RGNX) is 1.39

What is Regenxbio Inc dividend yield?

The dividend yield of Regenxbio Inc (RGNX) is 0.00%

What is the Market Cap of Regenxbio Inc?

The market capitalization of Regenxbio Inc (RGNX) is $419.65M

What is Regenxbio Inc’s stock symbol?

The stock symbol (or ticker) of Regenxbio Inc is RGNX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top